Compare Amer Sports Inc (AS) vs Ascendis Pharma A/S (ASND) Price & Performance

Amer Sports (AS) trades at $33.67, down 6.91% over 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.38 and revenue growth of 32% year-over-year, and raised full-year guidance. Key financials show a net income margin of 6.5% and positive cash flow from operations of $729.8 million in 2025.

The outlook is supported by analyst consensus with 12 buy ratings and a $58.67 price target, but risks include high valuation multiples like a P/E of 42.3 and competitive pressures in the sports apparel sector. Near-term focus is on Q2 2026 earnings due August 18, 2026, which could drive volatility.

Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.

ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.